Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Three-stage sequential statistical dissolution testing rules.

Yi Tsong1, Meiyu Shen, Vinod P Shah

  • 1Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Maryland, USA. tsong@cder.fda.gov

Journal of Biopharmaceutical Statistics
|October 8, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same author

Comparison of <i>in-vitro</i> release rates for vaginal systems.

Journal of biopharmaceutical statistics·2026
Same author

Statistical approaches for shelf-life determination of a drug product.

Journal of biopharmaceutical statistics·2026
Same author

Parallelism of four-parameter logistic bioassay models: equivalence testing for parameter differences.

Journal of biopharmaceutical statistics·2026
Same author

A survey of parallelism testing methods for bioassays.

Journal of biopharmaceutical statistics·2026
Same author

A multivariate equivalence test based on Mahalanobis distance with a data-driven margin.

Journal of biopharmaceutical statistics·2026
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

This study proposes a new dissolution testing plan to ensure drug product quality. The goal is to accept drug lots where at least 90% of tablets meet dissolution specifications, improving upon current USP and JP methods.

Area of Science:

  • Pharmaceutical Sciences
  • Drug Product Quality Control
  • Regulatory Science

Background:

  • Current pharmacopoeial dissolution testing (USP, EP, JP) lacks clear objectives for lot inference.
  • Existing methods are sensitive to mean dissolution, potentially failing to reject substandard drug lots.
  • Operating characteristic curves show limitations in detecting deviations from the specified dissolution limit Q.

Purpose of the Study:

  • To propose a dissolution test sampling plan with a defined objective for lot acceptance.
  • To ensure at least 90% of tablets dissolve above the specified limit Q at the designated time.
  • To develop a procedure that outperforms existing pharmacopoeial standards in controlling errors.

Main Methods:

  • Development of a group sequential procedure for dissolution testing.

Related Experiment Videos

  • Analysis of operating characteristic curves for proposed and existing methods.
  • Evaluation of type I error rate control under normality assumption.

    • Main Results:

    • The proposed sampling plan aims to accept lots with high dissolution compliance (≥90% above Q).
    • The derived group sequential procedure demonstrates improved control over the type I error rate compared to USP and JP.
    • The new method is more robust in identifying lots with potential dissolution issues.

    Conclusions:

    • The proposed dissolution test sampling plan offers a more reliable approach to ensuring drug product quality.
    • The group sequential procedure provides better statistical control than current USP and JP acceptance rules.
    • This advancement in dissolution testing can enhance patient safety by improving drug lot release decisions.